ArticleInternational journal for equity in health2025
Are tailored primary care services for social inclusion good value for money? A health economics evaluation with Monte-Carlo probabilistic sensitivity analysis comparing tailored social inclusion primary care services to mainstream primary care services for socially excluded people.
Article in International journal for equity in health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSocially excluded groups of people (SEP) live with resources so inadequate that it precludes them from participating fully in the normal acceptable living standards of society. They often have complex health and social care needs yet face structural and attitudinal barriers accessing mainstream healthcare. This can result in ambulatory-care sensitive conditions being left untreated in the community and contributes to the higher use of costly acute services in crisis mode by SEP. Tailored social inclusion primary care (SIPC) services can provide a flexible approach to engage with and meet the needs of this marginalised population. There is little evidence on the economic benefit of these services from the perspective of the publicly-funded health and social services. The aim of this study is to conduct an economic evaluation (cost-consequence analysis) of a single-centre SIPC clinic in the Mid-West region of Ireland over a 12-month period and to determine its value for money. The analysis compares cost outcomes between SEP who have access to a tailored SIPC service with those who do not.
methodsA cost analysis of the part-time SIPC service, based on available Irish-sourced data on the usage and costs of acute care in the Health Service Executive (HSE), and a literature review were used to identify the cost and outcome parameters of the economic framework. A multi-variate probabilistic sensitivity analysis using Monte Carlo Simulation methodology was used to assess model uncertainty.
resultsThe cost savings of investing in the part-time SIPC service providing care to 292 individuals, were estimated to be €718,890.90 with an estimated 658 bed days saved over a 12-month period. This represented a return of investment of €3.71 for every €1 spent. The sensitivity analysis supported the estimates with just a 2.2% likelihood of a negative return of investment.
conclusionThis study found that investment in SIPC services, that can meet the needs of a marginalised population, represents good value for money from the perspective of the publicly funded health service. The findings are valuable in supporting stakeholders, policy-makers, and budget holders to make evidence-informed equitable decisions for optimal funding allocation within health and social services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.